RSRC1, whose polymorphism is associated with altered brain function in schizophrenia, is a member of the serine and arginine rich-related protein family. Through homozygosity mapping and whole exome sequencing we show that RSRC1 mutation causes an autosomal recessive syndrome of intellectual disability, aberrant behaviour, hypotonia and mild facial dysmorphism with normal brain MRI. Further, we show that RSRC1 is ubiquitously expressed, and that the RSRC1 mutation triggers nonsensemediated mRNA decay of the RSRC1 transcript in patients' fibroblasts. Short hairpin RNA (shRNA)-mediated lentiviral silencing and overexpression of RSRC1 in SH-SY5Y cells demonstrated that RSRC1 has a role in alternative splicing and transcription regulation. Transcriptome profiling of RSRC1-silenced cells unravelled specific differentially expressed genes previously associated with intellectual disability, hypotonia and schizophrenia, relevant to the disease phenotype. Protein-protein interaction network modelling suggested possible intermediate interactions by which RSRC1 affects gene-specific differential expression. Patient-derived induced pluripotent stem cells, differentiated into neural progenitor cells, showed expression dynamics similar to the RSRC1-silenced SH-SY5Y model. Notably, patient neural progenitor cells had 9.6-fold downregulated expression of IGFBP3, whose brain expression is affected by MECP2, aberrant in Rett syndrome. Interestingly, Igfbp3-null mice have behavioural impairment, abnormal synaptic function and monoaminergic neurotransmission, likely correlating with the disease phenotype. Keywords: RSRC1; intellectual disability; alternative splicing; schizophrenia; IGFBP3 Abbreviations: iPSC = induced pluripotent stem cell; NPC = neural progenitor cell; RT-qPCR = real-time quantitative polymerase chain reaction; shRNA = short hairpin RNA; SNP = single nucleotide polymorphism
Introduction
RSRC1, previously termed SRrp53 (SR-related protein of 53 kDa), has an arginine and serine-rich domain and belongs to the SR-related polypeptide protein family. It is localized to nuclear speckles, where it binds other SRfamily proteins and the 35-kDa U2 small nuclear ribonucleoprotein (snRNP) auxiliary factor (U2AF 35 ). RSRC1 is therefore thought to have a role in both constitutive and alternative pre-mRNA splicing (Cazalla et al., 2005) . Recent studies demonstrate involvement of RSRC1 also in transcription regulation: RSRC1 interacts with the transcription factor oestrogen receptor b (ERb), which plays pivotal roles in the central nervous, endocrine, cardiovascular and immune systems; it represses ERb transcriptional activity by promoting PIAS1-mediated ERb SUMOylation (Chen et al., 2015) . Interestingly, a genome wide association study (GWAS) combined with neuro-imaging identified single nucleotide polymorphisms (SNPs) in RSRC1 associated with an endophenotype of schizophrenia (differential activation of the dorsolateral prefrontal cortex in working memory tasks measured by functional MRI) (Potkin et al., 2009 (Potkin et al., , 2010 . It is noteworthy, though, that the largest GWAS of schizophrenia, which included $37 000 patients and over $113 000 controls (Ripke et al., 2014) did not identify any significant SNPs in RSRC1. We now describe an autosomal recessive syndrome of early onset developmental delay, intellectual disability, aberrant behaviour, hypotonia and mild facial dysmorphic features and unravel the molecular pathways of the disease.
Materials and methods
Further details for all procedures are available in the Supplementary material.
Patients and genetic studies
Five siblings of consanguineous Bedouin kindred with similar phenotypes of developmental delay were referred to the Genetics Institute at Soroka Medical Center. As no diagnosis was achieved through standard clinical testing, further studies were initiated, assuming recessive heredity due to a founder mutation. DNA samples and skin punch biopsies were obtained following informed consent and approval of the Soroka Medical Center Internal Review Board (0316-14-SOR). Genome-wide linkage analysis, homozygosity mapping and whole-exome sequencing analysis were performed as previously described (Perez et al., 2016) .
Expression analysis
Total RNA was extracted from cultured cells using GENzol TM Tri RNA Pure Kit (Geneaid Biotech Ltd.) and real-time quantitative PCR (RT-qPCR) was done using standard methods. Protein lysates were extracted either from fibroblasts or SH-SY5Y silenced (short hairpin RNA, shRNA) cells and controls. Western blot analysis was done using rabbit anti-RSRC1 antibody (Abcam; ab106650). Relative protein levels were quantified measuring relative band intensities of RSRC1 to actin with Image Lab TM Software (Bio-Rad). RSRC1 expression analysis in normal human tissues was determined by RT-PCR.
RSRC1 overexpression and silencing constructs
Full cDNA sequence of RSRC1 was amplified from cDNA prepared of normal human brain tissue (Clontech Laboratories), cloned into pCDNA TM 3.1(À) expression vector. For shRNA-mediated RSRC1 silencing: shRNA oligo was designed to hybridize and silence the RSRC1 transcript; oligonucleotide was annealed and ligated into BamHI/EcoRI site of pGreenPuro TM lentival vector (System Biosciences). Lentivirus production and transduction of SH-SY5Y cells was conducted following guidelines by System Biosciences. RSRC1 silencing was assessed via RT-qPCR and western blotting for cells from each infection event separately.
E1A minigene in vivo alternative splicing assay SH-SY5Y cells were grown to $70% confluence and co-transfected with RSRC1-overexpressing and pMTE1A (provided by J. F. Cá ceres) plasmids (0.5 mg each). RSRC1 shRNA-silenced and shRNA control cells were transfected with the pMTE1A plasmid only (1 mg). Transfection was done using Lipofectamine Õ 2000. Cells were harvested 24 h post-transfection, RNA was extracted and cDNA was generated. Percentages of each amplified minigene isoform were calculated (Image Lab TM Software, Bio-Rad).
RNA sequencing analysis
RSRC1 knock-down and shRNA control cells (triplicates) were sequenced using Illumina's Hiseq-2500, single end 60. Genes demonstrating absolute fold change 52 and adjusted P-value 4 0.05 were considered as differentially expressed. Differential exon usage was inferred using DEXSeq (Anders et al., 2012) .
Gene ontology analysis and proteinprotein interaction network
Disease-associated enrichment of differentially expressed genes was done using the DAVID functional annotation tool (Huang et al., 2008 (Huang et al., , 2009 . Gene ontology (GO) clusters of differential exon usage genes were identified using the GO-Slim statistical overrepresentation test by PANTHER TM Version 12.0 (Thomas et al., 2003; Mi et al., 2013) (GO term analysis done without Bonferroni correction). Protein-protein interaction (PPI) network was generated using ResponseNet2.0 (Basha et al., 2013) .
Inducing and verifying pluripotent stem cells
Human STEMCCA Constitutive Polycistronic (OKSM) Lentivirus Kit (Millipore) was used for induced pluripotent stem cell (iPSC) generation (Sommer et al., 2009) . Cells of each clone were maintained and expanded following routine embryonic stem cell passaging and culturing protocols and were established as a human iPSCs line.
IPSC differentiation, fluorescenceactivated cell sorting and RT-qPCR Directed differentiation of iPSCs into neural lineage cells was performed as previously described (Kim et al., 2010) . Each clone was separately differentiated into neural progenitor cells (NPCs) at least three times. Total RNA and cDNA synthesis was done as described above from NCAM1-positive sorted neuronal cells. RT-qPCR of selected genes (Supplementary Table 3 ) was done using FastStart Universal SYBR Green master reaction master mix (Roche), followed by analysis and quantification using Rotor-Gene RG-3000 (Corbett Research).
Results

Clinical characterization
Five individuals of consanguineous Bedouin kindred ( Fig. 1A and Table 1 ) presented with an apparently autosomal recessive syndrome of severe global developmental delay (with no regression), intellectual disability with speech delay, aberrant behaviour and mild generalized hypotonia. All patients presented mild-to-moderate intellectual disability (no IQ tests were performed), with both motor and speech developmental delay, walking at 3-4 years of age and achieving verbal expression of only few single words even at adolescence. Patients had mild facial dysmorphism: broad nasal bridge, slight hypertelorism and retrognathia, open mouth and drooling. All had febrile seizures during childhood. Patient II-10 had focal seizures with impaired awareness (per ILAE 2017 criteria) that occasionally progressed to bilateral tonic-clonic seizures, and were effectively treated with valproic acid. There were no epileptiformic abnormalities on interictal EEG (no ictal EEG was recorded). All affected individuals had deficits in fine motor skills and incontinence, yet no abnormalities in coordination. Most notable were deficits in language comprehension and speech. Behavioural abnormalities were evident in all affected individuals, with temper tantrums, self-harm infliction and attention hyperactivity disorder (ADHD). One (Patient II-6) had autistic features. Aside from the above, detailed physical and neurological examination, ophthalmological and hearing tests were normal. All were born at term with normal birth weights following uneventful pregnancies. Karyotypes and chromosomal microarrays, as well as biochemical and metabolic work-up were normal, apart from slightly low free blood carnitine levels in all (data not shown). Brain MRI demonstrated no specific abnormal findings.
Genetic analysis
Genome-wide homozygosity mapping identified a single autozygous disease-associated $12 Mb locus on chromosome 3 between SNPs rs9848416 and rs863492 ( Fig. 1B ; maximal multipoint LOD score 3.4 at rs16832203; = 0). Whole-exome sequencing (Patient II-6, Fig. 1A ) identified a single deleterious variant within this locus: c.205C4T; p.Arg69* in RSRC1 (arginine and serine rich coiled-coil 1; transcript variant 1; NM_001271838.1). Wholegenome sequencing of affected Patients II-7 and II-11 (see Supplementary material for further details of methods) identified no other genomic mutations (coding or noncoding) within the chromosome 3 locus that are likely to be associated with the disease phenotype. The RSRC1 mutation, validated by Sanger sequencing, segregated within the family as expected ( Fig. 1A and C). Screening of 300 ethnically matched controls identified a single carrier and no homozygous mutants (data not shown). The mutation has not been previously reported in the genome Aggregation Database (gnomAD; http://gnomad.broadinstitute.org/). Only 15 RSRC1 loss-of-function variants have been reported in the Exome Aggregation Consortium (ExAC; http://exac.broadinstitute.org/), none in a homozygous state. RT-qPCR and western blot analyses of patients and unaffected fibroblasts showed that the c.205C4T mutation triggered nonsense-mediated decay, essentially constituting a null mutation ( Fig. 1D and E).
RSRC1 expression pattern and role in alternative splicing
In line with GTEx data (https://www.gtexportal.org/home/), RT-PCR demonstrated that RSRC1 is ubiquitously expressed in all human tissues examined (Fig. 1F) . RSRC1 expression was silenced in SH-SY5Y cells using lentiviral shRNA, achieving 490% silencing in terms of mRNA and 495% in RSRC1 protein levels ( Fig. 2A and B) . Standard in vivo E1A minigene assay of both RSRC1 knock-down (shRNA) and overexpressing SH-SY5Y cells showed marked statistically significant differences in relative levels of different E1A mini-gene isoforms compared to appropriate controls, highlighting RSRC1's role in alternative splicing (Fig. 2C-F) . 
Transcriptome analysis of RSRC1 knock-down SH-SY5Y cells
RNA-sequencing analysis of RSRC1-silenced SH-SY5Y cells identified 147 differentially expressed genes (Fig. 2G ). Of these, 101 were downregulated, 46 upregulated, and 12 were non-protein coding RNAs. Eight of the downregulated genes have been associated with intellectual disability, mental retardation, or hypotonia/muscle weakness/myopathy ( Fig. 2G and Supplementary Table 2) . Importantly, most phenotype-causing mutations within these eight genes are either loss-of-function or haploinsufficiency mutations. GO analysis of disease-associated genes enriched in our RNA-seq dataset identified 21 different disease clusters. Interestingly, of the five disease clusters with the lowest P-value were schizophrenia, Alzheimer's disease and dementia (Fig. 2H) . Furthermore, most disease-associated genes within these disease clusters were downregulated: 14 of 17 ($82%) in Alzheimer's disease, 11 of 16 ($69%) in schizophrenia, and three of four (75%) in dementia clusters (Fig. 2H) . GO analysis failed to recognize SLC7A11 as schizophrenia associated; it was manually added to this cluster for its known association in numerous publications of recent years (Bridges et al., 2012; Lin et al., 2016; McClatchy et al., 2016) . Ovarian cancer and type 2 diabetes clusters were also identified as statistically significant.
Protein-protein interaction network
Using ResponseNet we generated a sparse network connecting 93 of 135 differentially expressed genes. Within this network (not shown) we show only interactions of genes relevant to phenotypic features apparent in the syndrome described (Supplementary Table 2 and Fig. 2I ).
DEXSeq analysis
DEXSeq analysis identified 113 genes with differential exon usage, indicating that RSRC1 knock-down caused differences in alternative splicing patterns (Fig. 3A) . GO analysis of differential exon usage genes was done. Of cellular component enrichments, most notable are nucleus, ribosome and neuron projection terms, correlating with the subcellular localization and function of RSRC1. Focusing on biological process, notable are terms related to transcription, post-transcriptional modifications and RNA processing. Within molecular function terms, poly(A) RNA binding stands out (Fig. 3B) .
Transcription dynamics of iPSCs differentiated into neural progenitor lineage
Reprogrammed iPSC clones of a patient and an unaffected individual (Patient II-6 and Subject II-3, respectively) were differentiated into NPCs and fluorescence-activated cell sorted (FACS) for NCAM1 ( Fig. 3C and D) . Selected downregulated genes with relevance to the disease phenotype (Supplementary Table 1) , unravelled in our RSRC1 SH-SY5Y knock-down model, were chosen for gene expression inquiry via RT-qPCR in NPCs. Remarkably, most genes that were differentially expressed in our RSRC1 knock-down model were also differentially expressed in NPCs of affected versus unaffected individuals with statistically significant fold changes. Of the 25 genes tested, 19 showed statistically significant differential expression, Patient IDs correspond with pedigrees in Fig. 1A . + = positive; À = negative; AE = borderline, inconclusive; Bnb = broad nasal bridge; NA = not available; Rg = retrognathia.
RSRC1 intellectual disability syndrome Table 1) . Seven of eight genes that were downregulated in our RSRC1-silenced model and showed phenotypic association with the syndrome we describe (Supplementary Table 2 ) were also downregulated in NPCs (Supplementary Table 1) . Of the downregulated genes in affected NPCs, the most significant reduction in expression was $9.6-fold (near null) for IGFBP3 and $2.8-fold for IGFBP5 (Supplementary Table 1 ).
Discussion
Gene expression and alternative splicing constitute an important mechanism by which eukaryotic cells reach tissue and cell-specific fates (Tazi et al., 2009; Scotti and Swanson, 2016) . Somewhat counterintuitively, loss-of-function mutations in ubiquitous genes involved in regulation of gene expression often cause tissue-specific disease phenotypes (Lee and Young, 2013) . Numerous mutations in genes regulating alternative splicing have been shown to cause intellectual disabilities and other neurological disorders (Licatalosi and Darnell, 2006) . Such studies are conducive to deciphering mechanisms and pathways underlying neurological disorders as well as normal human neuro-development and function. While two previous studies suggested possible association of RSRC1 genetic variations with human diseases (schizophrenia and non-syndromic intellectual disability), they presented no proof of disease causation and no elucidation of molecular mechanisms (Potkin et al., 2009 (Potkin et al., , 2010 Maddirevula et al., 2018) . We now show that an RSRC1 mutation causes an autosomal recessive syndrome of global developmental delay and intellectual disability-most evident in speech acquisition, hypotonia, aberrant behaviour and mild facial dysmorphic features, with no structural brain defects. We further showed that the RSRC1 mutation triggers nonsense-mediated decay, degrading the RSRC1 truncated transcript, with practically null expression of the RSRC1 mature encoded protein ( Fig. 1D and E) . We demonstrate that RSRC1 is ubiquitously expressed in all human tissues examined, with slightly higher levels in brain, cerebellum, liver, colon, prostate, testes, placenta and whole blood cells (Fig. 1F) . Both the UK Brain Consortium (http://www.braineac.org/) and the Allen Human Brain Atlas (http://www.human.brain-map.org/) demonstrate that RSRC1 is expressed ubiquitously throughout the human brain. Although RSRC1 is expressed in the cerebellum, none of the affected individuals had cerebellarrelated phenotypes such as ataxia, suggesting redundancy of RSRC1 in the cerebellum. Autistic features, possibly reflecting cerebellar involvement, were seen only in one patient (Patient II-6) and are likely not part of the RSRC1-associated disease phenotype. Through an in vivo E1A minigene splicing assay, we showed that RSRC1 plays a role in alternative splicing (Fig. 2C-F) . To understand downstream molecular pathways of the disease better, we analysed the transcription profile of RSRC1 knock-down cells. Interestingly, mutations in eight genes downregulated in our RSRC1-silenced model are known to be associated with phenotypes related the syndrome we describe (Supplementary Table 2 ). Given the GWAS associating RSRC1 to schizophrenia (Potkin et al., 2009 (Potkin et al., , 2010 , it is of interest that the schizophrenia disease term was enriched in our experimental set-up (16 genes clustered), suggesting that RSRC1 might control expression of other schizophrenia-related genes (Fig. 2H) . The molecular pathways downstream of RSRC1 might also be implicated in the psychiatric manifestations found in the affected individuals studied (Table 1) .
RSRC1 silencing also downregulated expression of gene associated with Alzheimer's disease and dementia (Fig. 2H) . Although there is no proof of neurodegeneration in our patients, these findings might be associated with the disease pathophysiology. Moreover, the affected individuals in our cohort are young, and only further follow-up will unravel whether they develop psychiatric or neurodegeneration later on in life. Ovarian cancer and type 2 diabetes clusters were also identified as statistically relevant, though there is no obvious correlation to the disease phenotype; one possible explanation could stem from GO biases emerging due to vast genomic data over-representation of ovarian cancer and diabetes in existing databases. However, the relevance of these clusters may be because of other possibilities, such as similar disrupted mechanisms (e.g. immune response) or the multiple roles played by each gene (e.g. DNMT3A is a known oncogene and is also associated with neuro-psychiatric disorders). Through protein-protein interaction network of RSRC1 we elucidated possible pathways by which RSRC1 might regulate expression of specific genes (Fig. 2I) . DEXSeq and GO analysis of differential exon usage genes showed that RSRC1 can influence alternative splicing of specific genes which have a role in gene expression, post transcriptional modifications, RNA processing and possibly translation (Fig. 3A and B) . This indicates yet another layer of gene expression regulation mediated by RSRC1 role in alternative splicing.
To validate our RSRC1 knock-down model, we generated iPSCs of affected and unaffected wild-type siblings. After proving their pluripotency in vitro and in vivo (see 'Materials and methods' section), we differentiated iPSCs into neural progenitor lineage and collected cells positive to NCAM1 surface marker via FACS ( Fig. 3C and D) . Selected downregulated genes in the RSRC1 knock-down model, were tested (RT-qPCR) in neural progenitors differentiated from iPSCs. Remarkably, 19 of the 25 genes tested showed statistically significant differential expression similar to the downstream effects of RSRC1 silencing in SH-SY5Y cells (Supplementary Table 1) . Seven of eight genes that were downregulated in our RSRC1-silenced model and showed phenotypic association with the syndrome we describe (Supplementary Table 2) were also downregulated in patients NPCs (Supplementary Table 1 ). Four of these are associated with intellectual disability and mental retardation (SLC4A4, DNMT3A, GATM, VLDLR) and three with hypotonia, muscle weakness and myopathy (TNXB, TNNT1, ITGA7). Strikingly, the most significant reduction in expression in patients NPCs was in IGFBP3 ($9.6-fold, near null) and in IGFBP5 ($2.8-fold) (Supplementary Table 1 ). IGFBP3 and IGFBP5 are members of a family of insulin-like growth factor binding proteins. They bind insulin-like growth factors (IGF1 and IGF2) with high affinity and modulate cell growth, proliferation and apoptosis (Ferry et al., 1999) . In the developing brain, IGF1 plays many essential roles, acting in neuronal proliferation, maturation, survival, and growth (Beck et al., 1995; Russo et al., 2005) . It was previously shown that MECP2, whose mutations cause Rett syndrome, directly regulates the expression of IGFBP3 in human and mouse brains. MECP2 deficiency as well as MECP2 duplication syndrome in mice present similar phenotypes of mental retardation and autistic behaviour (Itoh et al., 2007) . Igfbp3-null mice exhibit reduction of dendritic spines and dendritic diameter thickening, abnormal synaptic function and monoaminergic neurotransmission, with consequent behavioural impairments (Dai et al., 2017) . Considering the near null expression levels of IGFBP3 in patients' NPCs, it is conceivable that the downregulation of IGFBP3 alone might have a considerable contribution to the neuronal disease phenotype (though regression, as seen in Rett syndrome, was not evident in our patients). The mechanism by which the RSRC1 mutation causes dramatic mis-expression of IGFBP3 demands further studies.
While mis-expression of IGFBP3 explains in part the neuronal phenotype of the disease, the facial dysmorphism and hypotonia (not described in Igfbp3-null mice) are likely mediated through other molecular pathways. IGF2 can stimulate both mitogenesis and myogenesis through its interaction and activation of the insulin-like growth factor 1 receptor (IGF1R). These seemingly contradicting cellular response switches are regulated by IGF2 in a mechanism not fully understood. IGFBP5, whose expression is downregulated in affected cells, is one of the major proteins secreted by skeletal muscles. It was shown that IGFBP5 knockdown impairs myogenesis and suppresses IGF2 gene expression (Ren et al., 2008) . Taking all this into account, it is conceivable that the hypotonia seen in the affected individuals might be caused through downstream mis-expression of IGFBP5. Overall, we delineate a human syndrome caused by RSRC1 mutation and elucidate specific downstream transcriptional and alternative splicing pathways that likely mediate, at least in part, both the neuronal and the muscular components of the disease phenotype.
Web resources
Genotype-Tissue Expression (GTEx) project: https://www. gtexportal.org/home/
